Standout Papers
- Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. (2002)
- The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study (2005)
Citation Impact
Citing Papers
SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase
2019 StandoutNobel
Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis
2016
Dorothy Hodgkin Lecture 2012* Non‐alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management
2012
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
2012
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
2023 StandoutNobel
Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)
2009
Genetic determinants of hepatic steatosis in man
2011
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
2018
Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions
2007
Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review
2012
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Effects of Liver Biopsy Sample Length and Number of Readings on Sampling Variability in Nonalcoholic Fatty Liver Disease
2008
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
2019
Targeting microbial biofilms: current and prospective therapeutic strategies
2017 Standout
Pathology of Nonalcoholic Fatty Liver Disease
2007
Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
2010 Standout
Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
2010
Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty Liver Disease
2008
NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice
2006
Pathology of fatty liver disease
2007
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
2006 Standout
ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis
2021
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes
2008
Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States
2017
Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis
2015
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
2012
Nonalcoholic Steatohepatitis in Children
2009
Association Between Puberty and Features of Nonalcoholic Fatty Liver Disease
2012
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years
2010
Psoriasis
2009 Standout
Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease
2009
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study
2011
Light to Moderate Alcohol Consumption Is Associated With Lower Frequency of Hypertransaminasemia
2007
NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men
2008
Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications
2013
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity
2009
Epidemiology of Hepatocellular Carcinoma
2013
Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease
2010
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
2008
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients
2013
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
2008
Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
2007 StandoutNobel
Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States
2012
A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France
2012
Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial
2004
Beyond Mortality
2010
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study
2011
Serum test for assessment of patients with Bence Jones myeloma
2003
The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity – A longitudinal cohort study
2019
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
2008
Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis
2011
Endpoints and clinical trial design for nonalcoholic steatohepatitis
2011
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease
2006
Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Risk in Obese Children and Adolescents
2012
Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study
2010
The metabolic syndrome
2010 Standout
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
2015
Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease
2011
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice
2016
Management of NAFLD: a stage-based approach
2016
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
2012
Liver Fat Content, Evaluated through Semi-Quantitative Ultrasound Measurement, Is Associated with Impaired Glucose Profiles: A Community-Based Study in Chinese
2013
Nonalcoholic Fatty Liver Disease Epidemic and Its Implications for Liver Transplantation
2013
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
2015 Standout
The Natural History of Non-Alcoholic Fatty Liver Disease
2010
Inflammatory Mechanisms in the Regulation of Insulin Resistance
2008
A position statement on NAFLD/NASH based on the EASL 2009 special conference
2010
Alterations in Ventricular Structure and Function in Obese Adolescents with Nonalcoholic Fatty Liver Disease
2012
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
2021 Standout
Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease
2008
Benefits of lifestyle modification in NAFLD
2007
Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis
2010 Standout
Incidence and natural course of fatty liver in the general population: The Dionysos study
2007
Association between nonalcoholic fatty liver disease and coronary artery disease
2007
Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy
2015
The changing landscape of atherosclerosis
2021 StandoutNature
Fitness Versus Fatness: Moving Beyond Weight Loss in Nonalcoholic Fatty Liver Disease
2010
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
2009
Pathological Features of Fatty Liver Disease
2014
Mechanisms and disease consequences of nonalcoholic fatty liver disease
2021
Prevalence and Trends in Obesity Among US Adults, 1999-2008
2010 Standout
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
2012
The medical complications of obesity
2006
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
2008 Standout
Severe Sepsis and Septic Shock
2013 Standout
Non-alcoholic fatty liver disease: The mist gradually clears
2008
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
2005 Standout
Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein
2010
Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis
2015
Bariatric Surgery Improves Histological Features of Nonalcoholic Fatty Liver Disease and Liver Fibrosis
2014
Relationship between resolution of non‐alcoholic steatohepatitis and changes in lipoprotein sub‐fractions: a post‐hoc analysis of the PIVENS trial
2019
Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up
2009
Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease
2007
Correlates and Heritability of Nonalcoholic Fatty Liver Disease in a Minority Cohort
2009
Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
2009 Standout
Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach
2007
Non-Alcoholic Fatty Liver Disease in Older People
2009
Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis
2009
From NAFLD in clinical practice to answers from guidelines
2013
Pharmacological agents for NASH
2013
Metabolic and histological features of non‐alcoholic fatty liver disease patients with different serum alanine aminotransferase levels
2008
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
2014
The NAFLD fibrosis score
2007 Standout
Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
2008
Nonobese Fatty Liver Disease
2016
Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?
2012
Independent effects of physical activity in patients with nonalcoholic fatty liver disease #
2009
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
2020
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
2018
Risk of Myocardial Infarction in Patients With Psoriasis
2006
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
2015 Standout
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study
2015
Acute respiratory distress syndrome 40 years later: Time to revisit its definition*
2008
Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile
2014
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
2020
The metabolic syndrome
2005 Standout
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
2006
The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years
2009
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
2013
The Association of Genetic Variability in Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) with Histological Severity of Nonalcoholic Fatty Liver Disease†
2010
Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers
2012
Non-alcoholic fatty liver disease
2021 Standout
Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study
2020
Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial
2013
Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography
2011
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD)
2012
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
2010
Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
2009
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
2009
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
2011 Standout
A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis
2009
Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease
2008
Toll-like receptors 1–9 are elevated in livers with fructose-induced hepatic steatosis
2011
Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
2011
Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (Flirt 2) Extension Trial
2009
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
2010
Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: Noninvasive Assessment with MR Elastography
2013
Effects of nonalcoholic fatty liver disease on the development of metabolic disorders
2006
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
2008
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
2013
Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis
2008
Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
2006 Standout
Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes
2015
Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity
2010
Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
2016
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
2013
Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis
2008
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design
2008
Non-alcoholic fatty liver disease and liver transplantation
2016
Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression
2011
Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism
2010
Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis
2019
Fatty liver incidence and predictive variables
2010
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
2007
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
2016
NAFLD, NASH and liver cancer
2013
Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
2009
Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver
2008
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
2017
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
2010 Standout
NASH and HCC
2009
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
2019
Ventilator-Induced Lung Injury
2013 Standout
HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
2009
Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
2013
Clinical and pathological progression of non‐alcoholic steatohepatitis to hepatocellular carcinoma
2012
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
2010
The global NAFLD epidemic
2013 Standout
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis
2007
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
2012
Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis
2013
Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile
2014
Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study
2008
Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study
2010
Patients With NASH and Cryptogenic Cirrhosis Are Less Likely Than Those With Hepatitis C to Receive Liver Transplants
2011
Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis
2015
Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD
2020
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Prognostic Value of Controlled Attenuation Parameter by Transient Elastography
2017
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
2014
IDENTIFYING NON-ALCOHOLIC FATTY LIVER DISEASE AMONG ASYMPTOMATIC OVERWEIGHT AND OBESE INDIVIDUALS BY CLINICAL AND BIOCHEMICAL CHARACTERISTICS
2009
High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis
2010
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
2006
Nonalcoholic fatty liver disease
2005 Standout
Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome
2008
Current treatment of severe sepsis
2006
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease
2008
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data
2017
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2008
Extrahepatic complications of nonalcoholic fatty liver disease
2013
Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis
2008
Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up
2012
Eight-Year Trend of Acute Respiratory Distress Syndrome
2010
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy
2015
Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes
2010
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
2010
Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients
2020
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
2010 Standout
Hepatocellular Carcinoma
2011 Standout
Lipid and polymer nanoparticles for drug delivery to bacterial biofilms
2014
Prevalence and Indicators of Portal Hypertension in Patients With Nonalcoholic Fatty Liver Disease
2012
Atherosclerosis
2001 Standout
Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis
2006
Increased risk of cardiovascular disease and chronic kidney disease in NAFLD
2012
Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease
2011
NAFLD: A multisystem disease
2015 Standout
Fatty liver is an independent predictor of early carotid atherosclerosis
2016
Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy
2011
Dietary Fat and Carbohydrates Differentially Alter Insulin Sensitivity During Caloric Restriction
2009
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis
2010
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
2004
The Genetic Approach in Pulmonary Fibrosis: Can It Provide Clues to This Complex Disease?
2006
Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease
2017
The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway
1999
Renal clearance of quantum dots
2007 StandoutNobel
High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease
2008
An apoptosis panel for nonalcoholic steatohepatitis diagnosis
2010
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma
2011
Clinical and Pathologic Features of Familial Interstitial Pneumonia
2005
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program
2012
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
2015
Diagnosis and Management of the Cardiac Amyloidoses
2005
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
2013
Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy
2011
Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial
2013
Nonalcoholic fatty liver disease‐related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma
2017
NASH and cryptogenic cirrhosis: A histological analysis
2009
Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
2015
Liver fibrosis scores predict liver disease mortality in the United States population
2017
Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis
2004
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
2010
Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease
2014
Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey
2014
TheF ramingham risk score and heart disease in nonalcoholic fatty liver disease
2012
Acute Respiratory Distress Syndrome
2012 Standout
De novo assembly of the Aedes aegypti genome using Hi-C yields chromosome-length scaffolds
2017 StandoutScience
Adaptive Response of T and B Cells in Atherosclerosis
2016
Enhanced Liver Fibrosis Test as a Reliable Tool for Assessing Fibrosis in Nonalcoholic Fatty Liver Disease in a Clinical Setting
2017
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
2013
Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study
2014
Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
2020
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
2017 Standout
Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study
2015
Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non‐invasive diagnosis of advanced fibrosis in biopsy‐proven non‐alcoholic fatty liver disease: a prospective study
2015
Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year‐community study
2017
Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real‐World Data From a Large U.S. Claims Database
2018
Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
2015
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
2009
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial
2009
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
2021
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
2015
Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease
2012
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
2016
Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients
2007
Ad Libitum Mediterranean and Low‐Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial
2018
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence
2006
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
2014 Standout
Bariatric surgery for non-alcoholic steatohepatitis in obese patients
2010
Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Cardiovascular Events in Type 2 Diabetic Patients
2007
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment
2017
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
2007 Standout
Fatty Liver
2007
Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity
2016
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
2009
Weight reduction for non-alcoholic fatty liver disease
2011
Identification of simple arylfluorosulfates as potent agents against resistant bacteria
2021 StandoutNobel
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases
2007
Modelling NAFLD disease burden in four Asian regions—2019‐2030
2020
Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate
2013 StandoutNobel
Human Fatty Liver Disease: Old Questions and New Insights
2011 StandoutScience
Updated thresholds for serum alanine aminotransferase level in a large‐scale population study composed of 34 346 subjects
2012
Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
2015
Coronary artery disease in decompensated patients undergoing liver transplantation evaluation
2018
Liver stiffness measurement predicts long‐term survival and complications in non‐alcoholic fatty liver disease
2019
Host-Gut Microbiota Metabolic Interactions
2012 StandoutScience
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
2017 Standout
No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial
2014
Lower rates of receiving model for end‐stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma
2016
Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
2013
Global cancer statistics, 2012
2015 Standout
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
2020
Rapid detection of structural variation in a human genome using nanochannel-based genome mapping technology
2014
Nonalcoholic Fatty Liver Disease
2015 Standout
Current Trends in Development of Liposomes for Targeting Bacterial Biofilms
2016
Review article: omega‐3 fatty acids – a promising novel therapy for non‐alcoholic fatty liver disease
2009
Obesity-Associated Liver Disease
2008
A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty Liver Disease
2017
Works of James Lymp being referenced
Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study
2005
Chronological development of elevated aminotransferases in a nonalcoholic population
2004
Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non‐alcoholic fatty liver disease
2005
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
2004
Familial Idiopathic Pulmonary Fibrosis
2005
Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial
2014
Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation*
2004
Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis
2006
Phase II studies of nebulised Arikace in CF patients withPseudomonas aeruginosainfection
2013
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease
2005
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
2005 Standout
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
2002 Standout
Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains
2002
Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma
2002
Reduction in apolipoprotein-mediated removal of cellular lipids by immortalization of human fibroblasts and its reversion by cAMP: lack of effect with Tangier disease cells
1999
715 Hyaluronic acid, an accurate serum marker for advanced fibrosis among nonalcoholic steatohepatitis
2003